产品中心Cell Resources
联系我们CONTACT US
400-999-210024小时服务热线
产品概述
人肝星状细胞
Cat NO.: CP-H046
-
产品名称：人肝星状细胞
-
组织来源：肝脏组织
-
产品规格：5×10⁵Cells/T25培养瓶
-
细胞简介：
人肝星状细胞分离自肝脏组织；肝脏是身体内以代谢功能为主的一个器官，并在身体里面起着去氧化、储存肝糖、分泌性蛋白质的合成等作用；肝脏也制造消化系统中之胆汁。肝脏是机体内脏里最大的器官，位于机体中的腹部位置，在右侧横隔膜之下，位于胆囊之前端且于右边肾脏的前方，胃的上方。肝脏是机体消化系统中最大的消化腺，为一红棕色的V字形器官。肝脏是尿素合成的主要器官，又是新陈代谢的重要器官。肝脏在机体位置和形态结构：肝脏位于右上腹，隐藏在右侧膈下和肋骨深面，大部分肝为肋弓所复盖，仅在腹上区、右肋弓间露出并直接接触腹前壁，肝上面则与膈及腹前壁相接。肝星状细胞（HSC）又名肝贮脂细胞、维生素A贮存细胞、窦周细胞、Ito细胞等，是肝脏细胞外基质的主要来源。HSC在激活后可进一步转化为肌成纤维细胞样细胞，各种可导致肝纤维化的因素均将HSC作为最终靶细胞。正常情况下，HSC处于静止状态，当肝脏发生炎症反应或受到机械刺激等损伤时，HSC的表型由静止型转变为激活型，激活的HSC可通过增生和分泌细胞外基质参与肝纤维化的形成及肝内结构的重建，此过程也是肝纤维化的中心环节。肝星状细胞分布于肝脏的Disse间隙内，是合成、分泌细胞外基质的主要来源，在肝纤维化的发生中处于最重要地位。肝星状细胞是肝脏特有的间充质细胞，约占肝脏细胞总数的8%-13%。作为肝脏合成细胞外基质的主要细胞群，肝星状细胞不仅能分泌蛋白多糖、糖蛋白等细胞外基质成分，合成一定量的胶原酶以维持正常的基底膜结构，还能通过其突起的收缩参与肝窦的微循环调节。此外，肝星状细胞能通过合成肝细胞生长因子、胰岛素样生长因子、表皮生长因子等促进肝细胞增殖和肝再生。
-
方法简介：
普诺赛实验室分离的人肝星状细胞采用混合酶灌流消化、低速离心、密度梯度离心制备而来，细胞总量约为5×10⁵cells/瓶。
-
质量检测：
普诺赛实验室分离的人肝星状细胞经α-SMA或Desmin免疫荧光鉴定，纯度可达90%以上，且不含有HIV-1、HBV、HCV、支原体、细菌、酵母和真菌等。
-
培养信息：
包被条件 培养基 含FBS、生长添加剂、Penicillin、Streptomycin等 产品货号 CM-H046 换液频率 每2-3天换液一次 生长特性 贴壁 细胞形态 成纤维细胞样 传代特性 可传3代左右 消化液 0.25%胰蛋白酶 人肝星状细胞体外培养周期有限；建议使用普诺赛配套的专用生长培养基及正确的操作方法来培养，以此保证该细胞的最佳培养状态。
参考文献
-
Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF pathways (2024-01-26)
作者：Yan-Ni Zhao:1.Joint Research Center on Medicine, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo, 315700, China. ; 2.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China. ; 3.College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju, Republic of Korea. ; Zhou-di Liu:1.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China. ; Tao Yan:1.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China. ; Ting-Xin Xu:1.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China. ; Tian-Yang Jin:1.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China. ; Yong-Sheng Jiang:1.Joint Research Center on Medicine, The Af
期刊：Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF pathways
DOI：10.1038/s41401-024-01226-7
影响因子 ：8.2
-
Targeting glutamine metabolism in hepatic stellate cells alleviates liver fibrosis (2022-11-14)
作者：Xiaochun Yin:1.Department of Gastroenterology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. ; Jin Peng:1.Hepatobiliary and Pancreatic Center & Liver Transplantation Center, the Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. ; Lihong Gu:1.Department of Gastroenterology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. ; Yan Liu:1.Department of Gastroenterology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. ; Xihan Li:1.Department of Gastroenterology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. ; Jinhui Wu:1.State Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center, Medical School, Nanjing University, Nanjing, 210093, China. ; 2.J
期刊：Targeting glutamine metabolism in hepatic stellate cells alleviates liver fibrosis
DOI：10.1038/s41419-022-05409-0
影响因子 ：9.7
引用产品： 人肝星状细胞 , HL-7702 [L-02; LO2] 细胞
-
miR-26a-5p protects against drug-induced liver injury via targeting bid (2011-01-20)
作者：Qian Zhang:1.Department of Geriatrics, the third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. ; Yan Liu:1.Department of Geriatrics, the third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. ; Yujie Yuan:1.Department of Neurology, The Gucheng County Hospital of Hebei Province, Hebei, China. ; Feifei Yao:1.Department of Geriatrics, the third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. ; Hongmei Zhang:1.Department of Geriatrics, the third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. ; Caiyan Zhao:1.Department of Infectious Diseases, the third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. ; Yanli Luo:1.Department of Geriatrics, the third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. ;
期刊：miR-26a-5p protects against drug-induced liver injury via targeting bid
DOI：10.1080/15376516.2021.2003919
影响因子 ：3.2
引用产品： 人肝星状细胞
-
Role of PML SUMOylation in arsenic trioxide-induced fibrosis in HSCs (2006-00-20)
作者：Jingyuan Dai:1.Department of Public Health, School of Medicine, Shihezi University, Shihezi, 832000, Xinjiang, China. ; Yunhua Hu:1.Department of Public Health, School of Medicine, Shihezi University, Shihezi, 832000, Xinjiang, China. ; Qiang Niu:1.Department of Public Health, School of Medicine, Shihezi University, Shihezi, 832000, Xinjiang, China. ; Guanling Song:1.Department of Public Health, School of Medicine, Shihezi University, Shihezi, 832000, Xinjiang, China. ; Haixia Wang:1.Department of Public Health, School of Medicine, Shihezi University, Shihezi, 832000, Xinjiang, China. ; Shugang Li:1.School of Public Health, Capital Medical University, No.10 Xitoutiao, You AnMen Wai, Beijing 100069, China. Electronic address: lishugang@ccmu.edu.cn. ;
期刊：Role of PML SUMOylation in arsenic trioxide-induced fibrosis in HSCs
影响因子 ：6.1
FAQs
Q：{{item.question}}
A：
产品资料
识别码示意图
